目的 Immune-mobilizing monoclonal TCRs against cancer(ImmTacs)can activate T cell to kill lung cancer cells efficitively,but it may not overcome immunosuppressive mechanisms,such as Tregs.Therefore we want to know whether iTregs impede the efficiency of ImmTacs,and if it does,what is the mechanism and how to deal with this problem.Therefore,the study is focused on iTregs inhibit the ImmTacs-redirected lung cancer cells lysis,in an effort to implement the immunotherapy preferable.We also demonstrated that iTregs through a series of mechanisms to suppress ImmTacs-redirected lung cancer cell killing and anti-PD1mAb can reverse the suppression function of iTregs.That is to say,combing ImmTacs with anti-PD-1 mAbs can produce a synergistic antitumor efficacy and this efficacy can resist the inhibition of iTregs.方法 1.Induction of iTreg by TGFb in vitro.2.Refold and purification of ImmTacs.3.CTL assays were used to detect the function of ImmTacs and iTregs.4.FACS was used to detect the mechanism of iTreg inhibited ImmTacs-redirected Lung cancer cells lysis.结果 1.iTreg can be induced in vitro successfully.2.ImmTacs can redirect T cells to lyse lung cancers.3.iTreg inhibit the function of immTacs.4.iTreg may be throgh inhibiting the expression of granzymeB,perforin,CD25,CD107a and proliferation of CD8+T cell to inhibit the function of ImmTacs.5.anti-PD1 mAb reverse the inhibition of iTregs on ImmTacs结论 Anti-PD-1 mAb can help ImmTacs play a better role in activated PBMC to lyse tumor cells and the combined efficacy could boycott the inhibition of iTregs.The findings provide proof-of-concept evidence for combined ImmTacs/αnti-PD-1 mAb treatment of advanced lung cancer.